S1B-408
Phase 2Small molecule
S1B-408 is one of 36 small molecule programs targeting Function. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Function
#DrugCompanyPhaseTrials
1Indocin
CCosette Pharmaceuticals, Inc.
Approved
Flomax
SanofiPhase 3
N-Acetyl Cyteien
SStanford University
Phase 3
Ezallor Sprinkle
AstraZenecaPhase 2
Golytely
BayerPhase 1
Activella
Eli LillyPreclinical
Spinraza
BiogenPreclinical
RAY1225
GGuangdong Raynovent Biotech Co., Ltd
Phase 1
GZR18
GGan & Lee Pharmaceuticals.
Phase 1
HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for S1B-408. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SS1 Biopharma, Inc.